32 results about "Endometrial Stromal Cell" patented technology

Disclosed herein is a method for culturing and proliferating hematopoietic stem cells or progenitor cells. The method comprises co-culturing the hematopoietic stem cells or the progenitor cells with human endometrial stromal cells so as to promote the expansion of hematopoietic stem cell-derived CD34⁺ cells or the growth of the progenitor cells. According to the disclosed method, unlike the prior methods of culturing the hematopoietic stem cells with the addition of cytokines, growth factors or hormones, the hematopoietic stem cells or the progenitor cells are co-cultured with the endometrial stromal cells or epithelial cells so that the number of CD34⁺-enriched hematopoietic stem cells or progenitor cells is increased by factors secreted from the endometrial stromal cells or epithelial cells. Accordingly, it is possible to eliminate the addition of growth factors, such as cytokines, and hormones, which cause problems in transplantation of hematopoietic stem cells or progenitor cells and thus safe hematopoietic stem cells or progenitor cells can be obtained in large amounts.

The invention provides a method for separating and purifying endometrial stromal cell and proceeding with large scale external culture, which improves the external purifying ratio and the breeding ability of endometrial stromal cell, adjusts the proliferative stage of endometrium and uterus physiology by treating adenotropic enthusiasm hormone and adenotropic ovulation hormone for the experimental animal, purifies the endometrial stromal cell with centrifuge method, establishes an external culture system with estrogen and gestagen in the cell purification and breeding, improves the breeding ability of the endometrial stromal cell, achieves a large scale breeding purpose and provides the abundant seed cell for the construction of the organizing engineer uterine tissue.

The invention belongs to the field of drug preparation, and relates to application of sodium hydrosulfide (NaHS) serving as a hydrogen sulfide donor in the drug preparation. The sodium hydrosulfide (NaHS) serving as the hydrogen sulfide donor is used for performing an experiment that H2S works on endometriosis and adhesion thereof through an endometrial stromal cell line, a C57 mouse endometriosis model and a Wistar rat uterine adhesion model. A result shows that the sodium hydrosulfide (NaHS) serving as the hydrogen sulfide donor can effectively inhibit IL-1beta induced endometrial mesenchymal cell inflammation; thermal hyperalgesia of an endometriosis model mouse can be obviously improved, so that lesion is reduced, fibrosis is relieved, and formation of postoperative adhesion of a uterine adhesion model rat can be inhibited; and the sodium hydrosulfide (NaHS) serving as the hydrogen sulfide donor can be further used for preparing a drug for treating the endometriosis and complications thereof.

The invention relates to the technical field of medicines, and provides applications of uterine cavity fluid-derived exosome in preparation of drugs and adjuvant therapeutic agents for treating infertility related diseases. Through the verification of experiments, exosome realizes the treatment or relieving of endometrial growth disorders by promoting the increasing of the thickness of endometrium, enhancing the activity of endometrial cells, reducing the damages to intimal cells, promoting VEGF expression, maintaining the dryness of endometrial stromal cells and stimulating proliferation; andthrough the realizing of the treating or relieving of maternal-fetal immune tolerance disorder-related diseases by achieving immune tolerance effects, treating spontaneous abortion and enhancing T helper lymphocyte levels, a novel theoretical basis can be provided for infertility treatment. In addition, for both fertilized eggs being fertilized in vivo or fertilized in vitro, the exosome can effectively enhance developmental rates in multiples; and implantation rates and farrowing rates of in vitro fertilization transplantation can be increased as well, so that positive auxiliary effects on infertility treatment can be achieved.

The invention relates to the technical field of medicines, and in particular to an application of an interleukin (IL-22) antibody in preparing medicines for treating adenomyosis (AD). According to the application provided by the invention, on the basis of research experiments that an angiogenesis promoting effect of endometrial ESC (endometrial stromal cell) of the AD can be inhibited by antagonizing the IL-22 and pathogenesis and progress of the AD can be inhibited subsequently, potential values of antagonizing the IL-22 (such as an IL-22 neutralizing antibody) in treating the AD is further assessed. Based upon results of in vitro experiments and in vivo animal tests, it is displayed that the IL-22 neutralizing antibody, which can take an obvious therapeutic effect on the adenomyosis, can be further used for preparing the medicines for treating the adenomyosis.

The invention discloses construction and identification of immortalized human endometriosis eutopic stromal cells (iheESCs), and relates to endometriosis. The invention relates to the iheESCs construction, and the identification of characteristics of iheESCs cells as endometrial stromal cells. A cell growth cycle of the constructed iheESCs cells is obviously prolonged, a proliferation rate, an estrogen/progesterone receptor, an EMT marker protein and the like are not changed, meanwhile, deciduation induction reaction, estrogen reaction and inflammatory reaction are changed, and the constructedcells do not have tumorigenicity. Therefore, compared with common primary cells, the constructed iheESCs have the characteristics of long growth cycle, stable phenotype and higher state activity, canbe suitable for research on endometriosis pathological mechanisms, endometrial receptive physiological mechanisms and the like, and have certain applicability in clinical experiments, medical biological experiments and the like.

The invention discloses a method for studying an action mechanism of Hsa_circ_0111659 in repairing of ESC by WJ-MSCs. According to the method, it is found that the hsa_circ_0111659 plays a positive regulatory role in repairing of injured stromal cells by the WJ-MSCs, and the proliferation of ESC can be reduced and the number of apoptotic cells in ESC can be increased by knocking down the hsa_circ_0111659. A targeting axis, namely the hsa_circ_0111659/miR-20b-5p/VEGF plays an important role in repair of endometria, and the hsa_circ_0111659 provides a new idea for the repair of endometrial stromal cells.

The invention relates to an artificial endometrium and its preparation and application and particularly relates to an artificial endometrium. The artificial endometrium comprises a biocompatible stent, endometrial stromal cells/epithelial cells and a mixed culture solution. Through a 3D bioprinting technology, the biocompatible stent and the endometrial stromal cells/epithelial cells are processedinto an artificial endometrium with bioactivity. The mixed culture solution comprises a medium and a biohormone. The biocompatible stent is prepared through a 3D printing method. The artificial endometrium can be used as a research tool for pathophysiological mechanisms aiming at artificial endometrial diseases, can be used as a screening model for regulating and affecting factors related to embryo implantation, and can be used as a research tool for preventing or treating directly or indirectly related endometrial lesions caused by any factor.

The invention discloses a bionic endometrium and a preparation method thereof. The bionic endometrium comprises two groups of BAMs (bionic amnions) in mirror symmetry, an ESC (endometrial stromal cells) is arranged between the two groups of BAMs, and according to the bionic endometrium and the preparation method thereof, the ESC is arranged between the two groups of BAMs in mirror symmetry. The BAM is formed in a sandwich structure mode, the hAAM on the two outer layers is provided with a double-layer basement membrane, rich natural fiber tissues are contained in the basement membrane, so that the mechanical strength of the membrane is improved, and the performance of converting the membrane into the endometrium is improved. Sufficient biomechanical strength close to the mechanical property of a fresh amnion can be formed through reinforcement from the front and rear aspects, and in addition, under the fixing action of clamping of the double-layer hAAM and field planting fusion of the hAMSCs, better tensile strength, elasticity and extension property are achieved.

The invention belongs to the technical field of medicine, and relates to novel pharmaceutical application of interleukin antibodies, in particular to application of interleukin IL-10 and IL-17 antibodies to preparation of a pharmaceutical composition for treating endometriosis. In vitro experiments and in vivo animal experiments show that IL-10 and IL-17A protein recombination can remarkably promote growth and invasion of endometrial stromal cells (ESC), and an IL-10 and IL-17A neutral antibody pharmaceutical composition can remarkably inhibit growth of an ectopic focus. Further, the interleukin antibodies can be used for preparing drugs for treating endometriosis.

The invention discloses application of AXL as a diagnosis and treatment target spot of intrauterine adhesion. It is found that AXL expression in endometrial scar tissue of an intrauterine adhesion patient is remarkably improved, activity is increased, expression of interstitial cells alpha-SMA and Collagen 1 is increased, then transdifferentiation of the interstitial cells to myofibroblasts is promoted, and the endometrial fibrosis process is accelerated. A human primary endometrial interstitial cell experiment and a mouse in-vivo experiment show that transdifferentiation of myofibroblasts can be prevented by applying the Bemcentinib, mouse endometrial fibrosis is improved, and the pregnancy rate and the live baby rate are increased. Therefore, AXL can play an important role in diagnosis of intrauterine adhesion and can be used for diagnosis of diseases. The inhibitor can be applied to medicines for treating intrauterine adhesion.

The invention discloses a method for measuring intracellular chlorine concentration or chloride channel gene CFTR expression of human endometrial stromal cells in a menstrual cycle so as to predict prognosis of endometrial deciduation related diseases of the human endometrial stromal cells. Intracellular chlorine concentration up-regulation and chlorine channel gene CFTR expression down-regulation in endometrial stromal cells in a menstrual cycle can hinder deciduation of the endometrial cells, and finally, repeated abortion/repeated implantation failure is caused. Restoration of CFTR expression and/or reduction of chloride ion concentration in endometrial stromal cells in a menstrual cycle can improve uterine decidualization and improve the outcome of recurrent abortion/recurrent implantation failure. The invention develops a new field for clinical prediction and treatment of recurrent abortion/recurrent implantation failure, and has a good application prospect.

The present invention relates to the use of pyrroloquinoline quinine (PQQ), its derivatives and/or salts for the preparation of drugs for the treatment and/or prevention of endometriosis including adenomyosis, chocolate cyst of ovary, deeply infiltrating endometriosis and other type of endometriosis. In addition, the present invention relates to the use of PQQ in combination with one or more the following antioxidants: N-Acetyl-L-cysteine (NAC), resveratrol, epigallocatechin gallate, vitamin E or vitamin C for the preparation of drugs for inhibiting the proliferation, oxidative stress status, invasion and migration of endometrial stromal cell. The use of PQQ in combination with NAC shows a synergistic effect on inhibiting cell proliferation: significantly inhibiting the proliferation of endometrial stromal cell in vitro; significantly reducing the damaged size of tissue caused by endometriosis in vivo; significantly reducing the infiltration of endometrial stroma and glands; significantly reducing the dose of NAC as well. PQQ is beneficial for fertility, and increases the chances of getting pregnant. PQQ alone or PQQ in combination with NAC generally shows no side effects and will not interfere with pregnancy.

The invention discloses application of Maqian essential oil in the preparation of a medicine for preventing and treating endometriosis. Primary cultured human ectopic endometrium stromal cell (ESC) is used as a model, and it is found through screening that Maqian essential oil has good activity of inhibiting endometriosis implantation and can inhibit TNF-alpha induced primary human ectopic endometrium stromal cell IL-8 secretion at low concentration (volume concentration is not lower than 0.001%) and inhibit human ectopic endometrium stromal cell proliferation and induce primary cultured human ectopic endometrium stromal cell apoptosis and necrosis at high concentration (volume concentration is not lower than 0.008%). Maqian essential oil as a Dai medicine component avoids many adverse reaction of Western medicine. The Maqian essential oil will not influence endocrine physiological function during medication and also will not influence normal reproduction requirement of female patients. The product has obvious clinic advantages.